Fig. 8: Schematic illustration depicting how gene therapy foam is freshly prepared and applied therapeutically to supply new genetic material or change existing DNA in cells.
From: Liquid foam improves potency and safety of gene therapy vectors
A Nonviral or viral vector (Therapeutic) is added to foam precursor in a syringe connected to a second syringe filled with air. The air and foam precursor are mixed by vigorously drawing the syringe plungers back and forth at least 30 times, creating a uniform microfoam consisting of gas bubbles separated by a network of interconnected liquid film structures called lamellae. Gene therapy vectors are concentrated in this liquid phase as the foam matures. B Once applied to tissue, the foam gradually deploys its therapeutic cargo and either supplies new genetic material or changes the endogenous DNA in the target cell.
